Mr. Martino Ciambrelli reports

VANTA ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT AND BOARD OF DIRECTORS UPDATE

Further to the news release dated May 29, 2026, Vanta Holdings Inc. has closed the first tranche of its previously announced non-brokered private placement through the issuance of 124,579 units of the company at a price of $1 per unit for aggregate gross proceeds of $124,579.42. Each unit consists of one common share in the capital of the company and one transferable common share purchase warrant. Each warrant entitles the holder to acquire one additional share at an exercise price of $1.25 per warrant share, exercisable until Aug. 21, 2028.

The securities issued under the private placement will be subject to a statutory hold period expiring Dec. 22, 2026.

The private placement remains in progress following the closing of the first tranche. The company expects to close the remaining portion of the private placement, in whole or in part, in one or more additional tranches, on or before Oct. 5, 2026, subject to compliance with the policies of the Canadian Securities Exchange.

Board of directors update

The company also announces, that Norman John Campbell has resigned from the company's board of directors, effective Aug. 21, 2026, as he transitions to a new professional opportunity as a partner in an asset management firm and seeks to avoid potential conflicts associated with his new role.

The company extends its sincere appreciation to Mr. Campbell for his long-standing service and contributions to Vanta, and wishes him continued success in this next chapter of his career.

Following Mr. Campbell's resignation, Vanta's board of directors is composed of four members, including two independent directors and two non-independent directors.

About Vanta Holdings Inc.

Vanta Holdings is a consumer health science and longevity company advancing an integrated ecosystem of United States-focused peptide therapy, nutraceutical and premium hydration products centred on preventative wellness and healthspan extension, positioning the company to participate in the rapidly expanding longevity economy.

Vanta is advancing a U.S.-focused telehealth-enabled peptide therapy and longevity platform leveraging commercialization infrastructure and Food and Drug Administration-registered 503A and 503B compounding pharmacy relationships to pursue initiatives across recovery, metabolic wellness, performance optimization and healthy aging categories.

Through its Vanta brand and select private-label partnerships, the company develops, manufactures and distributes premium hydration and longevity-oriented nutraceutical products, including, without limitation, its flagship proprietary Blackwater and BlackPowder product portfolio featuring bioactive compounds, trace mineral complexes and patented Fulvic Isolation Technology designed to support hydration, mineral replenishment, cellular function, immune function, gut health, nutrient absorption, cognitive function and broader everyday wellness-focused applications aligned with growing consumer demand for functional health optimization products. Vanta's vertically integrated operations include ownership of a natural alkaline spring water aquifer and a 40,000-square-foot Health Canada and HACCP-certified manufacturing facility situated in the mountains of British Columbia.

We seek Safe Harbor.